ERBB2 and colorectal carcinoma: Notably, a phase II trial, TRIUMPH study showed the promising efficacy of combination therapy with trastuzumab and pertuzumab for RASWT CRC harboring HER2 amplification confirmed by tissue and/or ctDNA [23].